Weeks after launch, Alex Zhavoronkov's AI-inspired longevity spinout sells to Hong Kong-listed group
When Alex Zhavoronkov unveiled Insilico’s longevity-focused spinout, he kept the precise amount of Series A funding under wraps — disclosing only that it’s in the “few million” dollar range — but had its marquee syndicate on full display.
Human Longevity, a collaborator, co-led the round with ETP Ventures and Performance Impact Venture Fund, flanked by BOLD Capital Partners, Longevity Vision Fund, Oculus co-founder Michael Antonov through Formic Ventures and LongeVC.
The lineup, alongside Deep Longevity’s promise of offering longevity as a service, was evidently sufficient to trigger a buyout for Hong Kong-listed Regent Pacific.
Zhavoronkov’s crew is bagging $3.79 million (HKD$29.56 million) from the takeover, which will see Deep Longevity become a subsidiary of Regent Pacific and a “core engine” of the longevity ecosystem it’s looking to build. In an email to Endpoints News, Zhavoronkov noted that Regent Pacific knows one of Deep Longevity’s target industry — insurance companies — and as much as its interest surprised the team, the deal was too attractive to turn down.
A key connection here was billionaire Jim Mellon, who’s board chairman at both Regent Pacific and Deep Longevity (“we commonly refer to him as the ‘longevity biotechnology Jesus,'” Zhavoronkov wrote). A long believer in Insilico, he had invested in Deep Longevity and is working with Wei-Wu He, the chairman of Human Longevity and “the longevity biotechnology Buddha,” on the board.
While Regent Pacific’s previous investments in the healthcare, wellness and life sciences sectors have taken it everywhere from an EMA-approved premature ejaculation treatment to CBD e-commerce, CEO Jamie Gibson said the long-term vision now is to transform into a “global end-to-end longevity and wellness biotechnology company.”
“It is only logical to start executing on this vision via the acquisition of the most sophisticated artificial intelligence system designed to track the rate of human aging and evaluate the effectiveness of longevity interventions,” he said in a statement.
I can not comment on the exact assets and forecasts for Regent Pacific but I am confident that the integration and future of the company will be very exciting and you are likely to be positively surprised more than once.
At its core, Deep Longevity’s main offering is a “deep aging clock” that determines a person’s true biological age by integrating multiple metrics from blood tests, microbiome analysis as well as voice and imaging input into a neural network.
As the anti-aging industry takes off, the idea is that being able to pinpoint why exactly someone is aging will be valuable information to a broad swath of clients: longevity and performance clinics, insurance companies, pharmaceutical companies, and even large employers with a workforce they’d like to retain.
“You cannot intervene if you cannot measure,” Zhavoronkov, who’s doubling as CEO, told Endpoints News upon launch.
The biotech spinout draws from Insilico’s expertise in artificial intelligence, a buzzword that’s garnered both enthusiasm and skepticism in an industry perennially yearning for shorter drug development timelines.
With Zhavoronkov remaining at the helm after the Regent takeover, its ultimate goal is to develop a standard-setting “longevity cloud” — a set of both universal and application-specific biomarkers of aging, including some that “people did not previously think about in the context of aging clocks.”
“I hope to be able to talk about it soon,” he wrote.